---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-025476"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:23:46.402080+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Pharma presents NPDR subset analysis from ZETA-1 Phase 2 trial for APX3330

## Summary
- Subset analysis: 3% of APX3330 vs 20% of placebo had ≥3-step worsening on binocular DRSS at Week 24.
- 7% of APX3330 vs 27% of placebo developed PDR (DRSS ≥61) in either eye at Week 24.
- APX3330 was well-tolerated; ocular AEs similar between groups, pruritus mild/self-limited.
- NPDR subset includes moderate-to-severe NPDR patients without CI-DME at baseline.
- Results inform planned trial of APX3330 to slow PDR conversion in high-risk NPDR.

## SEC filing metadata
- accession: 0001140361-24-025476
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036124025476/0001140361-24-025476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036124025476/ef20028889_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-025476
- JSON: https://secwatch.observer/filing/0001140361-24-025476.json
- Plain text: https://secwatch.observer/filing/0001140361-24-025476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.